Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tempest Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
TPST
Nasdaq
2836
www.tempesttx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tempest Therapeutics, Inc.
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
- Feb 10th, 2025 1:00 pm
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Feb 7th, 2025 9:30 pm
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
- Jan 6th, 2025 1:00 pm
A ‘Reverse Aging’ Guru’s Trail of Failed Businesses
- Dec 6th, 2024 2:00 am
Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock
- Nov 27th, 2024 10:20 am
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
- Nov 25th, 2024 9:30 pm
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
- Nov 12th, 2024 9:21 pm
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
- Nov 12th, 2024 1:00 pm
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
- Oct 10th, 2024 11:01 am
Tempest Extends Limited Duration Stockholder Rights Plan
- Oct 10th, 2024 11:00 am
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sep 20th, 2024 8:30 pm
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
- Sep 18th, 2024 12:00 pm
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 5th, 2024 12:00 pm
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
- Aug 21st, 2024 12:00 pm
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
- Aug 15th, 2024 12:00 pm
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
- Aug 8th, 2024 8:56 pm
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
- Jun 20th, 2024 12:00 pm
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
- Jun 18th, 2024 10:22 pm
Tempest to Participate in Upcoming Investor Conferences
- May 21st, 2024 12:00 pm
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
- May 9th, 2024 8:29 pm
Scroll